Abstract Library

#4439 Survival of 10,418 lung neuroendocrine tumours after surgical resection: Who needs follow-up and for how long?

Introduction: Surgical resection is the primary treatment for lung neuroendocrine tumours (NETs). The optimal follow-up period is debated in these patients.

Conference:

Presenting Author: El Asmar M

Authors: El Asmar M, Mortagy M, Chandrakumaran K, Ramage J,

Keywords: Lung, Neuroendocrine tumour, survival, surgery, follow-up period,

#4001 Sex differences in survival of neuroendocrine neoplasms (NENs): Comparative study of patients from National Cancer Registration and Analysis Service (NCRAS, UK) and Surveillance, Epidemiology, and End Results (SEER, US) databases

Introduction: It has been reported that sex is an important predictor of survival of NEN patients using data from the UK NCRAS database. The same statistical methods have not been applied to US SEER data.

Conference:

Presenting Author:

Authors: Mortagy M, El Asmar M, Chandrakumaran K, Ramage J,

Keywords: SEER, NCRAS, Neuroendocrine tumor, RMST, Cox regression, Survival analysis, Sex differences, RMTL, Kaplan Meier,

#3728 ACTH-secreting pancreatic neuroendocrine neoplasms – A case-series

Introduction: Ectopic Cushing’s syndrome occurs rarely in patients with pancreatic neuroendocrine neoplasms. Early recognition of symptoms is critical given the high morbidity and mortality associated with Cushing’s syndrome.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Hallanger-Johnson J, Haider M, Strosberg J,

Keywords: pancreatic neuroendocrine neoplasm, Cushing’s syndrome, ACTH, ectopic Cushing’s, neuroendocrine tumor,

#3722 A novel and potent Pb-212 alpha-particle therapy for NETs – Complete responses in mouse models to global clinical translation for NET patients

Introduction: A novel SSTR2 targeted peptide (VMT-alpha-NET) has been developed. Promising preclinical data have led to the initiation of multiple Phase 1 clinical trials in the United States for Pb-203 image-guided Pb-212 based alpha-particle therapy for NETs.

Conference:

Presenting Author: Schultz M

Authors: Schultz M, Johnson F, Li M, Liu D, McDonald M,

Keywords: NET, neuroendocrine tumor, alpha therapy, Pb-212, Pb-203, SPECT,

#3644 N-terminal pro-brain natriuretic peptide and chromogranin A as biomarkers for detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a serious complication for patients with neuroendocrine tumors (NETs), and early detection is crucial.

Conference:

Presenting Author: Lau T

Authors: Lau T, Johnson K, Oksjoki R, Baunwall S, Villadsen G,

Keywords: carcinoid heart disease, probnp, 5-hiaa, cga, biomarker,